Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population.

Abstract excerpt

Propafenone is an antiarrhythmic drug metabolized primarily by cytochrome P450 2D6 (CYP2D6). In adults, propafenone adverse events (AEs) are associated with CYP2D6 poor metabolizer status; however, pediatric data are lacking. Subjects were tested for 10 CYP2D6 allelic variants and copy number status, and activity scores assigned to each genotype. Seventy-six individuals (median 0.3 [range 0-26] years old) were...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anti-Arrhythmia Agents
• Share to Child